Conference Abstracts
Vol. 3, Issue Supplement 2, 2023 · S1-4
Effects of Next-Generation Sequencing on Lung Cancer Survivorship in Rural versus Urban Populations
Akshay Prakash,Amy Cripps
Submission received: 2023-12-02 / Published: 2023-12-15
BACKGROUND
The study serves to determine how next-generation sequencing (NGS) affects overall survivorship for lung cancer patients in three separate clinical settings. Targeted therapies demonstrate significant improvement in clinical outcomes1‑6 and now represent over 90% of the total oncology development pipeline.7
Table 1. Data Features
METHODS
The study was conducted on historical data with lung cancer patients diagnosed and seen in one of our community oncology clinics between 4/10/2022 and 3/20/2023. Clinical and social health data were collected and abstracted from patient medical history (Doctor's notes, Pathology studies, NGS results).
The data were compiled into a database containing the data features for each patient (Table 1).
Patients with incomplete data were excluded from the study, resulting in a population of n = 145.
RESULTS
The study included 145 patients diagnosed from 09.12.2009 to 03.31.2023. The median age was 72 years, with ages ranging from 49 – 96. The population included 76 females and 69 males. 85% of patients were identified as smokers (123 smokers, 21 non-smokers, 1 unknown). A median ECOG of 1 indicates high patient quality of life. 40% (58) of patients were surgical candidates. 61.9% (65) of late-stage (≥IIB) patients received NGS testing and 15% (10) are receiving targeted therapy based on the results. Population RECIST statuses are as follows:
Figure 1. No statistically significant differences seen in NGS on survival
Figure 2. LAF – Rural, DMC & NOA – Urban
Table 2. RECIST statuses - CR Complete Response 56 (34%), MR Mixed Response 3 (2%), PD Progressive Disease 17 (10%), PR Partial Response 12 (73%), SD Stable Disease 42 (25%), UK Unknown/Deceased 15 (9%)
CONCLUSION
Although NGS and the targeted therapies that follow are the next horizon for cancer treatment, in this relatively small population, with few actionable mutations, the results of our real-world dataset indicate no apparent overall survivorship advantages were conferred. Moreover, NGS testing percentages were highest at the rural clinic, not the urban clinics, elucidating testing patterns that contradict contemporary assumptions.
Moving forward, further studies should include other cancers and larger populations to further assess the obtained results.
REFERENCES
1. Journal of Thoracic Oncology. 2013;8(9):1148-1156.
2. Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials. Clinical Lung Cancer. 2012;13(2):107-114. doi:10.1016/j.cllc.2011.08.005
3. Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology. 2016;11(7):964-975. doi:10.1016/j.jtho.2016.04.014
4. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. doi:10.1056/nejmoa1606774
5. Arbour KC, Riely GJ. Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017;31(1):101-111. doi:10.1016/j.hoc.2016.08.012
6. Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495-509. doi:10.1038/s41568-019-0179-8
7. IQVIA Institute. Global oncology trends 2019. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019